89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH

May 2, 2024

https://www.globenewswire.com/news-release/2024/05/02/2874669/0/en/89bio-to-Host-Key-Opinion-Leader-Webinar-on-Pegozafermin-s-Opportunity-in-Advanced-MASH.html

SAN FRANCISCO, May 02, 2024 (GLOBE NEWSWIRE) — 89bio, Inc. (Nasdaq:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that it will host a key opinion leader (KOL) event of pegozafermin’s opportunity in advanced metabolic dysfunction-associated steatohepatitis (MASH) on Thursday, May 16, 2024 at 10:00am ET.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.